The Maybridge portfolio offers a comprehensive range of chemistry products and services tailored to the drug discovery and biotechnology sector. For 45 years, Maybridge has been at the forefront of innovative heterocyclic building block design, fuelled by the desire to access novel molecules of pharmaceutical interest.
The Maybridge portfolio is driven by a keen understanding of the needs of the medicinal chemist and is designed to expedite the drug discovery process through:
REACTIVE INTERMEDIATES. The core of the Maybridge building block collection, these pharmacophorically rich intermediates are specifically designed for medicinal chemistry, allowing logical SAR development and Hit-to-Lead optimization. Many will be of particular interest as “privileged structures” while others bearing solubilizing moieties add to the pharmacokinetic profile of drug molecules. Maybridge is proud to offer a selection of new, unique reactive intermediates each month as part of its promise to constantly deliver innovative new compounds for drug discovery research.
Belgium
